Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.56 |
| ▸ | TNKS | O95271 | 12/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025074 | 0.84 | PARP1 (0.54) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL3035403 | 0.84 | KDM4A (0.41) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL3040246 | 0.84 | PARP1 (0.43) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL3039605 | 0.81 | EGLN1 (0.43) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL10638241 | 0.80 | PARP1 (0.55) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL3030437 | 0.77 | HTR3A (0.52) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL3035787 | 0.75 | EGLN1 (0.64) | PARP1 | |
| SCHEMBL3031131 | 0.75 | PARP1 (0.41) | PARP1TNKSTNKS2 | |
| SCHEMBL3026678 | 0.75 | TUBB4A (0.48) | PARP1PARP14 | |
| SCHEMBL15693161 | 0.74 | SPR (0.42) | TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| EP-0161418-B1 | ANTIMICROBIAL AGENTS CONTAINING 2-(1H-PYRAZOL-1-YL)-4-(3H)-QUINAZOLINONES | BAYER AG (DE) | 1988-09-07 | — | — | EP | disclosed |
| US-4644000-A | FUNGICIDES, BACTERICIDES, SLIMICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-02-17 | — | — | US | disclosed |
| EP-0161418-A1 | Antimicrobial agents containing 2-(1H-pyrazol-1-yl)-4-(3H)-quinazolinones | BAYER AG (DE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | PARP1 637/4885TNKS 984/4885TNKS2 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.